|

Imzokitug Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-CCR8 Monoclonal Antibody BMS-986340, BMS 986340, BMS-986340, BMS986340

Pipeline

Phase 2: 1

Top Sponsors

  • Mayo Clinic1

Indications

  • Recurrent Pancreatic Adenocarcinoma1
  • Metastatic Pancreatic Adenocarcinoma1
  • Stage IV Pancreatic Cancer AJCC v81
  • Cancer1

Scottsdale, Arizona1 trial

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Mayo Clinic in Arizona

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.